ArchivesMagazine - 14 Jul 2016Niche drugs generate mainstream returns 178 billion reasons to look at orphan drug-makers 14 July 2016|Feature Issue: 14 Jul 2016 - Page 42 < Europe’s little gems Trading the big show > Issue: 14 Jul 2016 - Page 42 | Contents Next: Trading the big show Previous: Europe’s little gems Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Mark Dunne Issue Contents Chartist Mid cap plays Databank The Best & Worst Performers: FTSE 350, Global Market, Commodities, Forex, Sovereign Yields Diary Preview: Daily Mail & General Trust Director Deals Director dealings: Top buys & sells Have faith in CVS Exchange-Traded Funds How to invest in the food boom Feature MAKE YOUR INVESTMENTS THRIVE WITH SHARES LIVE Ride the rollercoaster Niche drugs generate mainstream returns The market's dividend 'Dogs' Rock solid income Trading the big show Forex Land of the rising yen Funds Europe’s little gems Mr Market Making the right decisions News Plunging rates a bad sign OneSavings battles downgrades Sterling dip good for Pinewood No end for jobs slowdown Melrose hyper-ventilates Activist targets Northgate Hot air out of Highlands Savannah’s vote of confidence News in brief: US businesses, AUS gambling, JPMorgan, RM, Premaitha, Aminex Opinion Hungry for income Personal Finance Has Brexit ruined your pension? Flight to safety Plays Capital rides mining revival Caring for growth Plays update: ASOS Plays update: Somero Enterprises Small Caps Best & Worst Performing Small Caps Table Golden boost for Shanta Profit with precious Joules Talking Point Shutting the liquidity trap Under The Bonnet Take a trip to Brighton Pier